https://doi.org/10.31288/oftalmolzh201436975

Structural changes of the retina, erythropoietin concentration in the vitreous body and peripheral blood in streptozotocin-induced diabetic rats in experiment (intermediate result)

NV Pasyechnikova, VA Naumenko, VV Vit, EV Ivanitskaya, TS Pilkevich

State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)

Introduction. Diabetes with its complications is one of the most important medical, social and economic problems of the health care today. According to the data of the WHO about 4 % of the world population suffer from diabetes, and in some countries it amounts up to 15 % and even to 20 % of population.

Purpose. To detect the character of structural changes of the retina and erythropoietin concentration in the vitreous body and peripheral blood, in streptozotocin-induced diabetic rats in experiment during the period of one month.

Methods. Wistar rats were included in the experiment. Diabetes was modeled by using a single intraperitoneal injection of streptozotocin in the dose of 65 mgper 1 kg of the body weight. All rats were divided into three groups. REpo administration started on the 1 Oth day in the dose of 6 units per 100 g of the body weight three times a week for a month.

Results. Subcutaneous REpo administration in the dose of 6 units per 100 g of the body weight three times a week for a month resulted in a significant increase of EPO concentration in the peripheral blood up to 90.2+7.9 and in the vitreous body — up to 545.7+ 17.67 in comparison with intact rats and rats with modeled diabetes. In a month the EPO concentration in the vitreous body increased significantly in streptozotocin-induced diabetic rats receiving REpo subcutaneously comparing with 2 weeks' follow-up. In rats with modeled diabetes the structural changes of the retina were noted, and the changes were more significant in 1 month term in comparison with 2 weeks' term. There was edema of the retina, vacuolar degeneration of the ganglion cells, blood vessel wall destruction, and focal hemor¬rhages. In the retina of diabetic rats receiving rEpo there were no changes mentioned above in 6 cases in 1 month. The changes detected in 4 cases consisted only in mild edema of the ganglion cell cytoplasm. Herewith disorders of their position architectonics and cell polymorphism were not noted. Distribution density of the ganglion cells was not decreased.There were no structural changes of blood vessels of different size located in the inner retinal layers. Key-words: streptozotocin-induced diabetes, recombinant erythr0poietin, diabetic retinopathy.

References

1.Linnik LA, Ganichenko IN, Maryshev YuA. Photocoagulation in treatment of severe diabetic retinopathy. Oftalmol Zh. 1977; 8:595- 600. Russian.

2.Astakhov YuS. Shadrichev FE. The diabetes centers — a new stage in the creation of specialized care to patients with diabetic retinopathy. Klin Oftalmol. 2001;2(4):19-25. Russian.

3.Astakhov YuS. Laser coagulation of the retina in diabetic retinopathy. Klin Oftalmol. 2000;1(1):36-8. Russian.

4.Kohner EM, Stratton I M, Aldington SJ et al. Six year progression of diabetic retinopathy in the UK Prospective Diabetes Study. Diabetic Med. 1996;13:14.

5.Baksheev VI, Kolomoyets NM. Erythropoietin in clinical practice. Klin. Meditsina. 2007;9:30-7. Russian.

6.Celik M, Gokmen N, Erbayraktar S et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. USA 2002;99:2258- 63.
Crossref

7.Mennini T, De Paola M, Bigini P et al. Nonhematopoi-etic  Erythropoietin Derivatives Prevent Motoneuron Degeneration in vitro and in vivo.Mol. Med. 2006; 12(7-8):153- 60.
Crossref

8.Bogoyevitch M. A. An update on the cardiac effects of Erythropoietin cardioprotection by erythropoietin and the lessons learn from studies in Bogoyevitch neuroprotection. Cardiovasc. Res. 2004;63:208- 16.
Crossref

9.Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 2006;18(2):132-8.
Crossref   Pubmed

10.Marti HH. Erythropoietin and the hypoxic brain. J. Exp. Biol.200;207(1):3233-42.
Crossref   Pubmed

11.Mathalone N, Altomare F, Sit M et al. Erythropoietin and its Receptors in Rat Models of Type I and II Diabetic Retinopathy. Invest. Ofhthalmol. Vis. Sci.2006;47(5):3865- 6.

12.Kolesnik YuM, Orlovskii MO, Kalinichenko MA, Grekova TA. Modification of resistance to diabetogenous factors influenced by chronic stress and adaptation to pe¬riodic hypoxia. Zaporozh. Med. Zhurnal. 2005; 3:21-6. Russian.